NVOS / Novo Integrated Sciences, Inc. - Documents déposés auprès de la SEC, rapport annuel, procuration

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest reported): April 30, 2025 Novo Integrated Sciences, Inc.

Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest reported): April 28, 2025 Novo Integrated Sciences, Inc.

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest reported): March 31, 2025 Novo Integrated Sciences, Inc.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest reported): March 7, 2025 Novo Integrated Sciences, I

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest reported): March 7, 2025 Novo Integrated Sciences, Inc.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest reported): February 20, 2025 Novo Integrated Science

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest reported): February 20, 2025 Novo Integrated Sciences, Inc.

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest reported): February 5, 2025 Novo Integrated Sciences, Inc.

NOVO INTEGRATED SCIENCES, INC. (Name of Registrant as Specified in Charter)

UNITED STATES OMB APPROVAL SECURITIES AND EXCHANGE COMMISSION OMB Number: 3235-0058 Washington, D.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 10-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended August 31, 2024 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from , 20 , to , 20. Commission File Number 001-40089 Novo Integrated Sci

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest reported): December 18, 2024 Novo Integrated Science

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest reported): December 18, 2024 Novo Integrated Sciences, Inc.

Description of registrant’s securities.

Exhibit 4.1 DESCRIPTION OF CAPITAL STOCK The following description of our capital stock is based upon our amended and restated articles of incorporation and our bylaws and applicable provisions of law, in each case as currently in effect. This discussion does not purport to be complete and is qualified in its entirety by reference to our amended and restated articles of incorporation, and our byla

Novo Integrated Sciences Reports 2024 Fiscal Year Financial Results

Exhibit 99.1 Novo Integrated Sciences Reports 2024 Fiscal Year Financial Results BELLEVUE, Wash., December 18, 2024 - Novo Integrated Sciences, Inc. (OTC Pink:NVOS) (the “Company” or “Novo”), pioneering a holistic approach to patient-first health and wellness through a multidisciplinary healthcare ecosystem of multiple patient and consumer touchpoints providing services and product innovation, tod

Subsidiaries of the Company.

Exhibit 21.1 LIST OF SUBSIDIARIES The following is a list of the direct and indirect subsidiaries of Novo Integrated Sciences, Inc. as of August 31, 2024. Company Jurisdiction of Incorporation or Organization Novo Healthnet Limited (1) Ontario, Canada Novomerica Health Group, Inc. (1) Nevada PRO-DIP, LLC (1) New York Acenzia, Inc. (2) Ontario, Canada Terragenx Inc. (3) Canada Clinical Consultants

NOVO INTEGRATED SCIENCES, INC. (Name of Registrant as Specified in Charter)

UNITED STATES OMB APPROVAL SECURITIES AND EXCHANGE COMMISSION OMB Number: 3235-0058 Washington, D.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest reported): November 22, 2024 Novo Integrated Science

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest reported): November 22, 2024 Novo Integrated Sciences, Inc.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest reported): November 20, 2024 Novo Integrated Science

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest reported): November 20, 2024 Novo Integrated Sciences, Inc.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest reported): November 20, 2024 Novo Integrated Science

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest reported): November 20, 2024 Novo Integrated Sciences, Inc.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest reported): November 7, 2024 Novo Integrated Sciences

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest reported): November 7, 2024 Novo Integrated Sciences, Inc.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest reported): November 7, 2024 Novo Integrated Sciences

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest reported): November 7, 2024 Novo Integrated Sciences, Inc.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest reported): November 4, 2024 Novo Integrated Sciences

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest reported): November 4, 2024 Novo Integrated Sciences, Inc.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest reported): October 25, 2024 Novo Integrated Sciences

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest reported): October 25, 2024 Novo Integrated Sciences, Inc.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest reported): October 17, 2024 Novo Integrated Sciences

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest reported): October 17, 2024 Novo Integrated Sciences, Inc.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. )

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Defin

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. )

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defin

Filing Fees Exhibit

Exhibit 107 CALCULATION OF FILING FEE TABLE Form S-8 (Form Type) Novo Integrated Sciences, Inc.

As filed with the Securities and Exchange Commission on September 23, 2024

As filed with the Securities and Exchange Commission on September 23, 2024 Registration No.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest reported): August 9, 2024 Novo Integrated Sciences,

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest reported): August 9, 2024 Novo Integrated Sciences, Inc.

Novo Integrated Sciences Reports Fiscal Year 2024 Third Quarter Financial Results

Exhibit 99.1 Novo Integrated Sciences Reports Fiscal Year 2024 Third Quarter Financial Results BELLEVUE, Wash., July 19, 2024 - Novo Integrated Sciences, Inc. (NASDAQ:NVOS) (the “Company” or “Novo”), pioneering a holistic approach to patient-first health and wellness through a multidisciplinary healthcare ecosystem of multiple patient and consumer touchpoints for services and product innovation, t

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest reported): July 19, 2024 Novo Integrated Sciences, I

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest reported): July 19, 2024 Novo Integrated Sciences, Inc.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended May 31, 2024 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from , 20, to , 20. Commission File Number: 001-40089 Novo Integrate

Novo Integrated Sciences Receives Commencement of Disbursement Notice for SBLC Leasing and Monetizing Program

Exhibit 99.1 Novo Integrated Sciences Receives Commencement of Disbursement Notice for SBLC Leasing and Monetizing Program BELLEVUE, Wash., July 18, 2024 - Novo Integrated Sciences, Inc. (NASDAQ: NVOS) (the “Company” or “Novo”) announced today that it has received notice of the commencement of disbursement for the complete monetization of a Standby Letter of Credit (“SBLC”). The initial disburseme

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest reported): July 18, 2024 Novo Integrated Sciences, I

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest reported): July 18, 2024 Novo Integrated Sciences, Inc.

SECURITIES AND EXCHANGE COMMISSION

UNITED STATES OMB APPROVAL SECURITIES AND EXCHANGE COMMISSION OMB Number: 3235-0058 Washington, D.

Registration Fee Table.

Exhibit 107 Calculation of Filing Fee Tables FORM S-1 (Form Type) NOVO INTEGRATED SCIENCES, INC.

Articles of Amendment to Articles of Incorporation, as amended, filed by the registrant with the Nevada Secretary of State on November 1, 2023 effective as of November 6, 2023

Exhibit 3.9

As filed with the U.S. Securities and Exchange Commission on July 8, 2024

As filed with the U.S. Securities and Exchange Commission on July 8, 2024 Registration No. UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 NOVO INTEGRATED SCIENCES, INC. (Exact name of registrant as specified in its charter) Nevada 8000 59-3691650 (State or other jurisdiction of incorporation or organization)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest reported): June 23, 2024 Novo Integrated Sciences, I

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest reported): June 23, 2024 Novo Integrated Sciences, Inc.

First Amendment to the Transaction Documents, dated as of June 23, 2024, by and between the registrant and Streeterville Capital, LLC (incorporated by reference to Exhibit 10.1 to the registrant’s Current Report on Form 8-K filed with the Commission on June 27, 2024).

Exhibit 10.1 FIRST AMENDMENT TO THE TRANSACTION DOCUMENTS THIS FIRST Amendment to THE Transaction Documents (as defined below) (this “Amendment”), is entered into as of June 23, 2024 (the “Effective Date”), by and between Novo Integrated Sciences, Inc., a Nevada corporation (the “Borrower”), and Streeterville Capital, LLC, a Utah limited liability company (the “Holder”). Each of the Borrower and H

Amendment to Executive Agreement, dated June 18, 2024, by and between the registrant and Christipher David (incorporated by reference to Exhibit 10.2 to the registrant’s Current Report on Form 8-K filed with the Commission on June 25, 2024).

Exhibit 10.2 Amendment to Employment Agreement [Christopher David] Dated as of June 18, 2024 This Amendment to Employment Agreement (this “Amendment”) dated as of the date first set forth above (the “Amendment Date”) is entered into by and between Novo Integrated Sciences, Inc., a Nevada corporation (the “Company”) and Christopher David (“Executive”). The Company and Executive may collectively be

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest reported): June 18, 2024 Novo Integrated Sciences, I

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest reported): June 18, 2024 Novo Integrated Sciences, Inc.

Amendment to Executive Agreement, dated June 18, 2024, by and between the registrant and GPE Global Holdings Inc. (incorporated by reference to Exhibit 10.1 to the registrant’s Current Report on Form 8-K filed with the Commission on June 25, 2024).

Exhibit 10.1 Amendment to Executive Agreement [GPE Global Holdings Inc. - Robert Mattacchione] Dated as of June 18, 2024 This Amendment to Executive Agreement (this “Amendment”) dated as of the date first set forth above (the “Amendment Date”) is entered into by and between Novo Integrated Sciences, Inc., a Nevada corporation (the “Company”) and GPE Global Holdings Inc. (“Executive”). The Company

Novo Integrated Sciences Receives Confirmation of Issuance of SBLC by HSBC for SBLC Leasing and Monetizing Program

Exhibit 99.1 Novo Integrated Sciences Receives Confirmation of Issuance of SBLC by HSBC for SBLC Leasing and Monetizing Program BELLEVUE, Wash., June 13, 2024 - Novo Integrated Sciences, Inc. (NASDAQ: NVOS) (the “Company” or “Novo”) announced today that it has received confirmation of the issuance of a Standby Letter of Credit (“SBLC”) by HSBC for delivery by Swift MT760, as part of a program desi

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest reported): June 13, 2024 Novo Integrated Sciences, I

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest reported): June 13, 2024 Novo Integrated Sciences, Inc.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest reported): June 6, 2024 Novo Integrated Sciences, In

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest reported): June 6, 2024 Novo Integrated Sciences, Inc.

Novo Integrated Sciences’ Board of Directors Approves Increase of Maximum Amount Under Stock Repurchase Program to $10 Million

Exhibit 99.1 Novo Integrated Sciences’ Board of Directors Approves Increase of Maximum Amount Under Stock Repurchase Program to $10 Million BELLEVUE, Wash., June 6, 2024 - Novo Integrated Sciences, Inc. (NASDAQ: NVOS) (the “Company” or “Novo”), today announced the Company’s Board of Directors has approved an increase of up to $10 million maximum amount, from the previously announced up to $5 milli

Acenzia Selected to Participate in Protein Industries Canada Program to Develop Plant Based Protein Products Project investment amounts expected to total $5.4 million with Acenzia investing $600 thousand, Protein Industries Canada investing $2.3 mill

Exhibit 99.1 Acenzia Selected to Participate in Protein Industries Canada Program to Develop Plant Based Protein Products Project investment amounts expected to total $5.4 million with Acenzia investing $600 thousand, Protein Industries Canada investing $2.3 million, and two other partner companies investing $2.5 million BELLEVUE, Wash., June 5, 2024 - Novo Integrated Sciences, Inc. (NASDAQ: NVOS)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest reported): June 5, 2024 Novo Integrated Sciences, In

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest reported): June 5, 2024 Novo Integrated Sciences, Inc.

Novo Integrated Sciences and RC Consulting Consortium Group Amend $70,000,000 Promissory Note

Exhibit 99.1 Novo Integrated Sciences and RC Consulting Consortium Group Amend $70,000,000 Promissory Note BELLEVUE, Wash., June 3, 2024 – Novo Integrated Sciences, Inc. (NASDAQ: NVOS) (the “Company” or “Novo”) announced today the Company and RC Consulting Consortium Group LLC, in favor of SCP Tourbillion Monaco (“RC”), have amended the prepayment terms and conditions of the previously disclosed $

Amendment, dated June 3, 2024, by RC Consulting Consortium Group LLC in favor of SCP Tourbillion Monaco and Novo Integrated Sciences, Inc. (incorporated by reference to Exhibit 10.1 to the registrant’s Current Report on Form 8-K filed with the Commission on June 3, 2024).

Exhibit 10.1 AMENDMENT This Amendment (the “Amendment”) to the Promissory Note, dated April 26, 2023 (the “RC Note”), between RC Consulting Consortium Group LLC (“RC”) in favor of SCP Tourbillion Monaco and Novo Integrated Sciences Inc. (the “Company”) is made this 3rd day of June, 2024. WHEREAS, it is in the best interest of all parties to facilitate this Amendment in connection with the RC Note.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest reported): June 3, 2024 Novo Integrated Sciences, In

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest reported): June 3, 2024 Novo Integrated Sciences, Inc.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest reported): May 31, 2024 Novo Integrated Sciences, In

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest reported): May 31, 2024 Novo Integrated Sciences, Inc.

Novo Integrated Sciences’ Board of Directors Conducting Strategic Review to Increase Maximum Amount under Stock Repurchase Program

Exhibit 99.1 Novo Integrated Sciences’ Board of Directors Conducting Strategic Review to Increase Maximum Amount under Stock Repurchase Program BELLEVUE, Wash., May 31, 2024 – As previously reported, the Board of Directors (the “Board”) of Novo Integrated Sciences, Inc. (NASDAQ: NVOS) (the “Company” or “Novo”) approved the repurchase of up to $5 million of the Company’s outstanding common stock fr

Novo Integrated Sciences Receives Confirmation of Ready, Willing and Able (RWA) Issued by HSBC for SBLC Leasing and Monetizing Program

Exhibit 99.1 Novo Integrated Sciences Receives Confirmation of Ready, Willing and Able (RWA) Issued by HSBC for SBLC Leasing and Monetizing Program BELLEVUE, Wash., May 30, 2024 - Novo Integrated Sciences, Inc. (NASDAQ: NVOS) (the “Company” or “Novo”) announced today that as part of a program to monetize a Standby Letter of Credit (“ SBLC”), the Company has received written confirmation that a Rea

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest reported): May 30, 2024 Novo Integrated Sciences, In

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest reported): May 30, 2024 Novo Integrated Sciences, Inc.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended February 29, 2024 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from , 20, to , 20. Commission File Number: 001-40089 Novo Inte

Novo Integrated Sciences Reports Fiscal Year 2024 Second Quarter Financial Results

Exhibit 99.1 Novo Integrated Sciences Reports Fiscal Year 2024 Second Quarter Financial Results BELLEVUE, Wash., April 15, 2024 - Novo Integrated Sciences, Inc. (NASDAQ:NVOS) (the “Company” or “Novo”), pioneering a holistic approach to patient-first health and wellness through a multidisciplinary healthcare ecosystem of multiple patient and consumer touchpoints for services and product innovation,

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest reported): April 15, 2024 Novo Integrated Sciences,

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest reported): April 15, 2024 Novo Integrated Sciences, Inc.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest reported): April 5, 2024 Novo Integrated Sciences, I

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest reported): April 5, 2024 Novo Integrated Sciences, Inc.

Guaranty, dated as of April 5, 2024, by and between Acenzia Inc. and Streeterville Capital, LLC (incorporated by reference to Exhibit 10.4 to the registrant’s Current Report on Form 8-K filed with the Commission on April 11, 2024).

Exhibit 10.4 GUARANTY THIS GUARANTY (“Guaranty”), dated as of April 5, 2024, is made by Acenzia Inc., an Ontario corporation (the “Guarantor”), in favor of Streeterville Capital, LLC, a Utah limited liability company (the “Lender”) (together with the Guarantor, the “Parties”). W I T N E S S E T H: WHEREAS, Lender is making a loan (the “Loan”) to NOVO INTEGRATED SCIENCES, INC., a Nevada corporation

Securities Purchase Agreement, dated as of April 5, 2024, by and between Novo Integrated Sciences, Inc. and Streeterville Capital, LLC (incorporated by reference to Exhibit 10.2 to the registrant’s Current Report on Form 8-K filed with the Commission on April 11, 2024).

Exhibit 10.2 Securities Purchase Agreement This Securities Purchase Agreement (this “Agreement”), dated as of April 5, 2024, is entered into by and between Novo Integrated Sciences, Inc., a Nevada corporation (“Company”), and Streeterville Capital, LLC, a Utah limited liability company, its successors and/or assigns (“Investor”). A. Company and Investor are executing and delivering this Agreement

Security Agreement, dated as of April 5, 2024, by and between Novo Integrated Sciences, Inc. and Streeterville Capital, LLC (incorporated by reference to Exhibit 10.3 to the registrant’s Current Report on Form 8-K filed with the Commission on April 11, 2024).

Exhibit 10.3 Security Agreement This Security Agreement (this “Agreement”), dated as of April 5, 2024, is executed by Novo Integrated Sciences, Inc., a Nevada corporation (“Debtor”), in favor of Streeterville Capital, LLC, a Utah limited liability company (“Secured Party”). A. Debtor issued to Secured Party a certain Secured Promissory Note of even date herewith, as may be amended from time to tim

Promissory Note, dated as of April 5, 2024, by and between Novo Integrated Sciences, Inc. and Streeterville Capital, LLC (incorporated by reference to Exhibit 10.1 to the registrant’s Current Report on Form 8-K filed with the Commission on April 11, 2024).

Exhibit 10.1 SECURED CONVERTIBLE PROMISSORY NOTE April 5, 2024 U.S. $6,210,000.00 FOR VALUE RECEIVED, Novo Integrated Sciences, Inc., a Nevada corporation (“Borrower”), promises to pay to Streeterville Capital, LLC, a Utah limited liability company, or its successors or assigns (“Lender”), $6,210,000.00 and any interest, fees, charges, and late fees accrued hereunder on the date that is twelve (12

Guaranty, dated as of April 5, 2024, by and between Novo Healthnet Limited and Streeterville Capital, LLC (incorporated by reference to Exhibit 10.5 to the registrant’s Current Report on Form 8-K filed with the Commission on April 11, 2024).

Exhibit 10.5 GUARANTY THIS GUARANTY (“Guaranty”), dated as of April 5, 2024, is made by Novo Healthnet Limited, an Ontario corporation (the “Guarantor”), in favor of Streeterville Capital, LLC, a Utah limited liability company (the “Lender”) (together with the Guarantor, the “Parties”). W I T N E S S E T H: WHEREAS, Lender is making a loan (the “Loan”) to NOVO INTEGRATED SCIENCES, INC., a Nevada c

Novo Integrated Sciences Closes on $6,210,000 Securities Purchase Agreement Both the Mast Hill $3,500,000 Note and the FirstFire $277,777 Note were Paid in Full with Cash Proceeds from the Streeterville Note

Exhibit 99.1 Novo Integrated Sciences Closes on $6,210,000 Securities Purchase Agreement Both the Mast Hill $3,500,000 Note and the FirstFire $277,777 Note were Paid in Full with Cash Proceeds from the Streeterville Note BELLEVUE, Wash., April 11, 2024 - Novo Integrated Sciences, Inc. (NASDAQ: NVOS) (the “Company” or “Novo”) announced today the Company has entered into a securities purchase agreem

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest reported): April 4, 2024 Novo Integrated Sciences, I

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest reported): April 4, 2024 Novo Integrated Sciences, Inc.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest reported): March 26, 2024 Novo Integrated Sciences,

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest reported): March 26, 2024 Novo Integrated Sciences, Inc.

Novo Integrated Sciences Provides Update on Certain Current Actions and Events

Exhibit 99.1 Novo Integrated Sciences Provides Update on Certain Current Actions and Events BELLEVUE, Wash., March 26, 2024 - Novo Integrated Sciences, Inc. (NASDAQ: NVOS) (the “Company” or “Novo”), today provides an update with respect to certain actions and events, as follows: ● Purchase and Sale Agreement – Ophir Collection: As previously disclosed, on November 21, 2023 Novo entered into a Purc

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest reported): March 19, 2024 Novo Integrated Sciences,

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest reported): March 19, 2024 Novo Integrated Sciences, Inc.

Limited Waiver, dated March 19, 2024, by RC Consulting Consortium Group LLC (incorporated by reference to Exhibit 10.1 to the registrant’s Current Report on Form 8-K filed with the Commission on March 19, 2024).

Exhibit 10.1 rc consulting consortium group llc 2431 McCall Ct., Douglasville, GA. 30135, USA Novo Integrated Sciences, Inc. 11120 NE 2nd Street, Suite 100 Bellevue, Washington State 98004 LIMITED WAIVER Date: March 19, 2024 WAIVER; REPRESENTATION AND WARRANTY. The Waiver set forth herein shall be limited precisely as written and relates solely to the Securities Purchase Agreement, dated April 26,

Assignment of Security Purchase Agreement and Promissory Note, dated March 18, 2024, by and among the registrant, RC Consulting Group LLC and RC Consulting Consortium Group LLC (incorporated by reference to Exhibit 10.1 to the Company’s Current Report on Form 8-K filed with the Commission on March 18, 2024).

Exhibit 10.1 ASSIGNMENT OF SECURITY PURCHASE AGREEMENT AND PROMISSORY NOTE THIS ASSIGNMENT OF SECURITY PURCHASE AGREEMENT AND PROMISSORY NOTE (“Assignment”), is made as of this 18th day of March, 2024, by and between RC Consulting Group LLC, (“Assignor”), RC Consulting Consortium Group LLC, (“Assignee”), and Novo Integrated Sciences Inc. (“Company”), (Assignor, Assignee and Company are sometimes r

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest reported): March 18, 2024 Novo Integrated Sciences,

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest reported): March 18, 2024 Novo Integrated Sciences, Inc.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest reported): February 21, 2024 Novo Integrated Science

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest reported): February 21, 2024 Novo Integrated Sciences, Inc.

Novo Integrated Sciences Subsidiary, Clinical Consultants International, Signs Agreement with Futura Surgicare Pvt Ltd.

Exhibit 99.1 Novo Integrated Sciences Subsidiary, Clinical Consultants International, Signs Agreement with Futura Surgicare Pvt Ltd. BELLEVUE, Wash., February 21, 2024 - Novo Integrated Sciences, Inc. (NASDAQ: NVOS) (the “Company” or “Novo”), and Clinical Consultants International, LLC (“CCI”), a Novo wholly-owned subsidiary, today announced the signing of a Consulting Services Agreement (the “Agr

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest reported): February 16, 2024 Novo Integrated Science

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest reported): February 16, 2024 Novo Integrated Sciences, Inc.

Limited Waiver dated as of February 16, 2024 by and between the registrant and RC Consulting Group LLC in favor of SCP Tourbillion Monaco.

Exhibit 10.1 rc consulting group llc 4311 School House Commons Suite #386, Harrisburg, NC. 28075 Novo Integrated Sciences, Inc. 11120 NE 2nd Street, Suite 100 Bellevue, Washington State 98004 LIMITED WAIVER Date: February 16, 2024 WAIVER; REPRESENTATION AND WARRANTY. The Waiver set forth herein shall be limited precisely as written and relates solely to the Securities Purchase Agreement, dated Apr

Novo Integrated Sciences Receives Limited Waiver to Securities Purchase Agreement for $70,000,000 Promissory Note The Waiver Exempts any determination of non-compliance associated to Nasdaq’s Minimum Bid Price Requirement Rule

Exhibit 99.1 Novo Integrated Sciences Receives Limited Waiver to Securities Purchase Agreement for $70,000,000 Promissory Note The Waiver Exempts any determination of non-compliance associated to Nasdaq’s Minimum Bid Price Requirement Rule BELLEVUE, Wash., February 20, 2024 - Novo Integrated Sciences, Inc. (NASDAQ: NVOS) (the “Company” or “Novo”) announces today the Company has received a Limited

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest reported): February 16, 2024 Novo Integrated Science

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest reported): February 16, 2024 Novo Integrated Sciences, Inc.

Novo Integrated Sciences Appoints New President

Exhibit 99.1 Novo Integrated Sciences Appoints New President BELLEVUE, Wash., February 16, 2024 - Novo Integrated Sciences, Inc. (NASDAQ: NVOS) (the “Company” or “Novo”) announces today Mr. Robert Oliva has been appointed as the Company’s new President. Mr. Oliva succeeds Mr. Christopher David, who remains as the Company’s Chief Operating Officer and as a member of the Company’s Board of Directors

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest reported): February 9, 2024 Novo Integrated Sciences

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest reported): February 9, 2024 Novo Integrated Sciences, Inc.

US67011T3005 / NOVO INTEGRATED SCIENCES INC / Hudson Bay Capital Management LP - NVOS 13GA Passive Investment

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* Novo Integrated Sciences, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 67011T300 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule

Novo Integrated Sciences Reports Fiscal Year 2024 First Quarter Financial Results

Exhibit 99.1 Novo Integrated Sciences Reports Fiscal Year 2024 First Quarter Financial Results BELLEVUE, Wash., January 22, 2024 - Novo Integrated Sciences, Inc. (NASDAQ:NVOS) (the “Company” or “Novo”), pioneering a holistic approach to patient-first health and wellness through a multidisciplinary healthcare ecosystem of multiple patient and consumer touchpoints for services and product innovation

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended November 30, 2023 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from , 20, to , 20. Commission File Number: 001-40089 Novo Inte

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest reported): January 22, 2024 Novo Integrated Sciences

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest reported): January 22, 2024 Novo Integrated Sciences, Inc.

NOVO INTEGRATED SCIENCES, INC. (Name of Registrant as Specified in Charter)

UNITED STATES OMB APPROVAL SECURITIES AND EXCHANGE COMMISSION OMB Number: 3235-0058 Washington, D.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest reported): December 19, 2023 Novo Integrated Science

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest reported): December 19, 2023 Novo Integrated Sciences, Inc.

Blacksheep Trust Files Partial Assignment of $1 Billion Dollar Gold Backed Bond to Novo Integrated Sciences

Exhibit 99.1 Blacksheep Trust Files Partial Assignment of $1 Billion Dollar Gold Backed Bond to Novo Integrated Sciences BELLEVUE, Wash., December 19, 2023 - Novo Integrated Sciences, Inc. (NASDAQ: NVOS) (the “Company” or “Novo”) announces today Blacksheep Trust (“Blacksheep”), a New York-based private express trust settled for the purposes of Benevolent Services with (i) a 33% allocation to chari

Description of registrant’s securities.

Exhibit 4.1 DESCRIPTION OF CAPITAL STOCK The following description of our capital stock is based upon our amended and restated articles of incorporation and our bylaws and applicable provisions of law, in each case as currently in effect. This discussion does not purport to be complete and is qualified in its entirety by reference to our amended and restated articles of incorporation, and our byla

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest reported): December 14, 2023 Novo Integrated Science

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest reported): December 14, 2023 Novo Integrated Sciences, Inc.

Subsidiaries of the Company.

Exhibit 21.1 LIST OF SUBSIDIARIES The following is a list of the direct and indirect subsidiaries of Novo Integrated Sciences, Inc. as of August 31, 2023. Company Jurisdiction of Incorporation or Organization Novo Healthnet Limited (1) Ontario, Canada Novomerica Health Group, Inc. (1) Nevada PRO-DIP, LLC (1) New York Acenzia, Inc. (2) Ontario, Canada Terragenx Inc. (3) Canada Clinical Consultants

2023 Equity Incentive Plan.

Exhibit 10.54 Novo Integrated Sciences, Inc. 2023 Equity Incentive Plan Table of Contents Article I. Purposes and Definitions 1 Section 1.01 Purposes of this Plan; Structure. 1 Section 1.02 Definitions. 1 Section 1.03 Additional Interpretations. 5 Article II. Stock Subject to this Plan; Administration. 5 Section 2.01 Stock Subject to this Plan. 5 Section 2.02 Administration of this Plan. 6 Section

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 10-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended August 31, 2023 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from , 20 , to , 20. Commission File Number 001-40089 Novo Integrated Sci

Novo Integrated Sciences Reports 2023 Fiscal Year Financial Results

Exhibit 99.1 Novo Integrated Sciences Reports 2023 Fiscal Year Financial Results BELLEVUE, Wash., December 14, 2023 - Novo Integrated Sciences, Inc. (NASDAQ:NVOS) (the “Company” or “Novo”), pioneering a holistic approach to patient-first health and wellness through a multidisciplinary healthcare ecosystem of multiple patient and consumer touchpoints providing services and product innovation, today

Compensation Recovery Policy dated November 22, 2023.

Exhibit 97.1 COMPENSATION RECOVERY POLICY Effective November 22, 2023 Novo Integrated Sciences, Inc. (the “Company”) is committed to strong corporate governance. As part of this commitment, the Company’s Board of Directors (the “Board”) has adopted this Compensation Recovery Policy (the “Policy”). The Policy is intended to further the Company’s pay-for-performance philosophy and to comply with app

Novo Integrated Sciences Signs Master Collaboration Agreement with Psychocare Health Pvt. Ltd. India

Exhibit 99.1 Novo Integrated Sciences Signs Master Collaboration Agreement with Psychocare Health Pvt. Ltd. India BELLEVUE, Wash., December 5, 2023 - Novo Integrated Sciences, Inc. (NASDAQ: NVOS) (the “Company” or “Novo”) proudly announces the signing of a Master Collaboration Agreement with Psychocare Health Pvt. Ltd. India (“PCHPL”). This partnership initiates a strategic initiative to introduce

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest reported): December 5, 2023 Novo Integrated Sciences

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest reported): December 5, 2023 Novo Integrated Sciences, Inc.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest reported): December 4, 2023 Novo Integrated Sciences

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest reported): December 4, 2023 Novo Integrated Sciences, Inc.

Novo Integrated Sciences’ Purchase and Sale Agreement to Acquire Ophir Collection Receives Court Approval

Exhibit 99.1 Novo Integrated Sciences’ Purchase and Sale Agreement to Acquire Ophir Collection Receives Court Approval BELLEVUE, Wash., December 4, 2023 - Novo Integrated Sciences, Inc. (NASDAQ: NVOS) (the “Company” or “Novo”) today announced the United States District Court for the Central District of California has approved the Purchase and Sale Agreement (“PSA”) which provides for the Company t

NOVO INTEGRATED SCIENCES, INC. (Name of Registrant as Specified in Charter)

UNITED STATES OMB APPROVAL SECURITIES AND EXCHANGE COMMISSION OMB Number: 3235-0058 Washington, D.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest reported): November 21, 2023 Novo Integrated Science

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest reported): November 21, 2023 Novo Integrated Sciences, Inc.

Purchase and Sale Agreement, dated November 21, 2023, by and between the registrant Blake Alsbrook, solely in his capacity as Court-appointed successor receiver in Ocean Thermal Energy Corporation v. C. Robert Coe II, et al., United States District Court for the Central District of California Case No. 2:19-cv-04299 VAP (JPRx) (incorporated by reference to Exhibit 10.1 to the registrant’s Current Report on Form 8-K filed with the Commission on November 27, 2023).

Exhibit 10.1 PURCHASE AND SALE AGREEMENT This PURCHASE AND SALE AGREEMENT (“Agreement”) is entered into on November 21, 2023 between Novo Integrated Sciences Inc. (“Buyer”) and Blake Alsbrook (“Seller”), solely in Seller’s capacity as Court-appointed Successor Receiver in Ocean Thermal Energy Corporation v. C. Robert Coe II, et al., United States District Court for the Central District of Californ

Novo Integrated Sciences Regains Compliance with Nasdaq Minimum Bid Price Requirement

Exhibit 99.1 Novo Integrated Sciences Regains Compliance with Nasdaq Minimum Bid Price Requirement BELLEVUE, Wash., November 24, 2023 - Novo Integrated Sciences, Inc. (NASDAQ: NVOS) (the “Company” or “Novo”) today announced the Company has received notice from The Nasdaq Capital Market, LLC (“Nasdaq”), dated November 22, 2023, informing Novo that it has regained compliance with the minimum bid pri

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest reported): November 22, 2023 Novo Integrated Science

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest reported): November 22, 2023 Novo Integrated Sciences, Inc.

Novo Integrated Sciences Advised Receipt of Proceeds of RC Consulting Promissory Note Expected in 3-5 Business Days

Exhibit 99.1 Novo Integrated Sciences Advised Receipt of Proceeds of RC Consulting Promissory Note Expected in 3-5 Business Days BELLEVUE, Wash., November 6, 2023 - Novo Integrated Sciences, Inc. (NASDAQ: NVOS) (the “Company” or “Novo”) today announced that RC Consulting Group LLC (“RC”) has advised that the final phase for the withdrawal/payment to Novo of the unsecured 15-year $70,000,000 promis

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest reported): November 6, 2023 Novo Integrated Sciences

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest reported): November 6, 2023 Novo Integrated Sciences, Inc.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest reported): November 6, 2023 Novo Integrated Sciences

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest reported): November 6, 2023 Novo Integrated Sciences, Inc.

Novo Integrated Sciences Announces Reverse Stock Split

Exhibit 99.1 Novo Integrated Sciences Announces Reverse Stock Split BELLEVUE, Wash., November 6, 2023 - Novo Integrated Sciences, Inc. (NASDAQ: NVOS) (the “Company” or “Novo”), today announced that the Company will undertake a reverse stock split of its common stock at a ratio of 1-for-10 (the “Reverse Stock Split”). The Reverse Stock Split is expected to become effective immediately after the clo

Novo Integrated Sciences Announces Issuance of Underlying One Billion Dollar Gold Backed Bond

Exhibit 99.1 Novo Integrated Sciences Announces Issuance of Underlying One Billion Dollar Gold Backed Bond BELLEVUE, Wash., November 3, 2023 - Novo Integrated Sciences, Inc. (NASDAQ: NVOS) (the “Company” or “Novo”) today announced the issuance of the underlying One Billion Dollar gold backed bond (the “Bond”) specific to the previously disclosed Master Collateral Transfer Agreement. The issuance o

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest reported): November 3, 2023 Novo Integrated Sciences

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest reported): November 3, 2023 Novo Integrated Sciences, Inc.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest reported): October 24, 2023 Novo Integrated Sciences

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest reported): October 24, 2023 Novo Integrated Sciences, Inc.

Novo Integrated Sciences’ Board of Directors Approves $5 Million Stock Repurchase Program

Exhibit 99.1 Novo Integrated Sciences’ Board of Directors Approves $5 Million Stock Repurchase Program BELLEVUE, Wash., October 24, 2023 - Novo Integrated Sciences, Inc. (NASDAQ: NVOS) (the “Company” or “Novo”), today announced the Company’s Board of Directors has approved the repurchase of up to $5 million of the Company’s outstanding common stock (“shares”) from time to time in the open market a

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest reported): October 9, 2023 Novo Integrated Sciences,

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest reported): October 9, 2023 Novo Integrated Sciences, Inc.

Letter of Funding Commitment, dated May 5, 2023, from Sheikh Khaled bin Mohammad bin Fahad Al Thanayan.

Exhibit 99.2

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest reported): October 6, 2023 Novo Integrated Sciences,

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest reported): October 6, 2023 Novo Integrated Sciences, Inc.

Novo Integrated Sciences Provides Update on Certain Current Events

Exhibit 99.1 Novo Integrated Sciences Provides Update on Certain Current Events BELLEVUE, Wash., October 6, 2023 - Novo Integrated Sciences, Inc. (NASDAQ: NVOS) (the “Company” or “Novo”) today provides an update with respect to the following previously disclosed pending transactions: (i) the Blacksheep Trust One Billion Dollar Master Collateral Transfer Agreement (the “Collateral Transfer Facility

Transcript of NOVO INTEGRATED SCIENCES, INC. 2023 Virtual Annual Meeting of Stockholders September 29, 2023

Exhibit 99.1 Transcript of NOVO INTEGRATED SCIENCES, INC. 2023 Virtual Annual Meeting of Stockholders September 29, 2023 Chris David: Hello to everyone. Welcome to Novo Integrated Sciences’ 2023 Virtual Annual Meeting of Stockholders. My name is Chris David. I am Novo’s President and COO, and a member of the Board. I will be moderating today’s meeting. At the conclusion of the formal business port

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest reported): September 29, 2023 Novo Integrated Scienc

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest reported): September 29, 2023 Novo Integrated Sciences, Inc.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest reported): September 27, 2023 Novo Integrated Scienc

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest reported): September 27, 2023 Novo Integrated Sciences, Inc.

Master (Asset Transfer) Agreement, dated as of September 27, 2023, by and between the registrant and Blacksheep Trust (incorporated by reference to Exhibit 10.1 to the registrant’s Current Report on Form 8-K filed with the Commission on September 28, 2023).

Exhibit 10.1 MASTER (ASSET TRANSFER) AGREEMENT This MASTER AGREEMENT (this “Agreement”), dated as of September 27, 2023, is entered into by and between Blacksheep Trust (the “Asset Holder”) and Novo Integrated Sciences Inc. (the “Recipient”), collectively the “Parties”. RECITALS WHEREAS, the Asset Holder controls certain verifiable collateral (“Collateral”); WHEREAS the Asset Holder desires to tra

Novo Integrated Sciences Signs Master Collateral Transfer Agreement One Billion Dollar Collateral Transfer through Blacksheep Trust

Exhibit 99.1 Novo Integrated Sciences Signs Master Collateral Transfer Agreement One Billion Dollar Collateral Transfer through Blacksheep Trust BELLEVUE, Wash., September 28, 2023 - Novo Integrated Sciences, Inc. (NASDAQ: NVOS) (the “Company” or “Novo”), today announced Novo and Blacksheep Trust have signed a One Billion Dollar Master Collateral Transfer Agreement (the “Master Agreement”) for the

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest reported): September 27, 2023 Novo Integrated Scienc

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest reported): September 27, 2023 Novo Integrated Sciences, Inc.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. )

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)

Amendment to the registrant’s bylaws, dated September 27, 2023 (incorporated by reference to Exhibit 3.1 to the registrant’s Current Report on Form 8-K filed with the Commission on September 27, 2023).

Exhibit 3.1 Amendment to Bylaws Of NOVO INTEGRATED SCIENCES, INC. a Nevada corporation Adopted September 27, 2023 The Bylaws of NOVO INTEGRATED SCIENCES, INC. are hereby amended as follows: Section 2.6 of the Bylaws is hereby amended and restated in its entirety to provide as follows: 2.6 Quorum. The holders of one-third (33⅓%) of the stock issued and outstanding and entitled to vote thereat, pres

Promissory Note, dated as of September 18, 2023, by and between Novo Integrated Sciences, Inc. and FirstFire Global Opportunities Fund, LLC (incorporated by reference to Exhibit 10.1 to the registrant’s Current Report on Form 8-K filed with the Commission on September 22, 2023).

Exhibit 10.1 NEITHER THE ISSUANCE AND SALE OF THE SECURITIES REPRESENTED BY THIS CERTIFICATE NOR THE SECURITIES INTO WHICH THESE SECURITIES ARE CONVERTIBLE HAVE BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR APPLICABLE STATE SECURITIES LAWS. THE SECURITIES MAY NOT BE OFFERED FOR SALE, SOLD, TRANSFERRED OR ASSIGNED (I) IN THE ABSENCE OF (A) AN EFFECTIVE REGISTRATION STATEMENT FOR

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest reported): September 18, 2023 Novo Integrated Scienc

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest reported): September 18, 2023 Novo Integrated Sciences, Inc.

Guaranty, dated as of September 18, 2023, by and between Acenzia Inc. and FirstFire Global Opportunities Fund, LLC (incorporated by reference to Exhibit 10.3 to the registrant’s Current Report on Form 8-K filed with the Commission on September 22, 2023).

Exhibit 10.3 GUARANTY THIS GUARANTY (“Guaranty”), dated as of September 18, 2023, is made by Acenzia Inc., an Ontario corporation (the “Guarantor”), in favor of FirstFire Global Opportunities Fund, LLC, a Delaware limited liability company (the “Lender”) (together with the Guarantor, the “Parties”). W I T N E S S E T H: WHEREAS, Lender is making a loan (the “Loan”) to NOVO INTEGRATED SCIENCES, INC

Securities Purchase Agreement, dated as of September 18, 2023, by and between Novo Integrated Sciences, Inc. and FirstFire Global Opportunities Fund, LLC (incorporated by reference to Exhibit 10.2 to the registrant’s Current Report on Form 8-K filed with the Commission on September 22, 2023).

Exhibit 10.2 SECURITIES PURCHASE AGREEMENT This SECURITIES PURCHASE AGREEMENT (the “Agreement”), dated as of September 18, 2023, by and between NOVO INTEGRATED SCIENCES, INC., a Nevada corporation, with headquarters located at 11120 NE 2nd Street, Suite 100, Bellevue, WA 98004 (the “Company”), and FIRSTFIRE GLOBAL OPPORTUNITIES FUND, LLC, a Delaware limited liability company, with its address at 1

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. )

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defin

Novo Integrated Sciences Provides Update on Certain Current Actions and Events September 29, 2023 Shareholder Meeting Voting Update

Exhibit 99.1 Novo Integrated Sciences Provides Update on Certain Current Actions and Events September 29, 2023 Shareholder Meeting Voting Update BELLEVUE, Wash., September 21, 2023 - Novo Integrated Sciences, Inc. (NASDAQ: NVOS) (the “Company” or “Novo”), today provides an update with respect to certain actions and events, as follows: ● Annual Meeting Shareholder Voting. For shareholders that have

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest reported): September 21, 2023 Novo Integrated Scienc

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest reported): September 21, 2023 Novo Integrated Sciences, Inc.

Press release of the registrant dated September 21, 2023.

Exhibit 99.1 Novo Integrated Sciences Provides Update on Certain Current Actions and Events September 29, 2023 Shareholder Meeting Voting Update BELLEVUE, Wash., September 21, 2023 - Novo Integrated Sciences, Inc. (NASDAQ: NVOS) (the “Company” or “Novo”), today provides an update with respect to certain actions and events, as follows: ● Annual Meeting Shareholder Voting. For shareholders that have

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest reported): September 12, 2023 Novo Integrated Scienc

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest reported): September 12, 2023 Novo Integrated Sciences, Inc.

Promissory Note, dated as of September 12, 2023, by and between Novo Integrated Sciences, Inc. and Mast Hill Fund, L.P. (incorporated by reference to Exhibit 10.1 to the registrant’s Current Report on Form 8-K filed with the Commission on September 18, 2023).

Exhibit 10.1 NEITHER THE ISSUANCE AND SALE OF THE SECURITIES REPRESENTED BY THIS CERTIFICATE NOR THE SECURITIES INTO WHICH THESE SECURITIES ARE CONVERTIBLE HAVE BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR APPLICABLE STATE SECURITIES LAWS. THE SECURITIES MAY NOT BE OFFERED FOR SALE, SOLD, TRANSFERRED OR ASSIGNED (I) IN THE ABSENCE OF (A) AN EFFECTIVE REGISTRATION STATEMENT FOR

Securities Purchase Agreement, dated as of September 12, 2023, by and between Novo Integrated Sciences, Inc. and Mast Hill Fund, L.P. (incorporated by reference to Exhibit 10.2 to the registrant’s Current Report on Form 8-K filed with the Commission on September 18, 2023).

Exhibit 10.2 SECURITIES PURCHASE AGREEMENT This SECURITIES PURCHASE AGREEMENT (the “Agreement”), dated as of September 12, 2023, by and between NOVO INTEGRATED SCIENCES, INC., a Nevada corporation, with headquarters located at 11120 NE 2nd Street, Suite 100, Bellevue, WA 98004 (the “Company”), and MAST HILL FUND, L.P., a Delaware limited partnership, with its address at 48 Parker Road, Wellesley,

Guaranty, dated as of September 12, 2023, by and between Acenzia Inc. and Mast Hill Fund, L.P. (incorporated by reference to Exhibit 10.3 to the registrant’s Current Report on Form 8-K filed with the Commission on September 18, 2023).

Exhibit 10.3 GUARANTY THIS GUARANTY (“Guaranty”), dated as of September 12, 2023, is made by Acenzia Inc., an Ontario corporation (the “Guarantor”), in favor of Mast Hill Fund, L.P., a Delaware limited partnership (the “Lender”) (together with the Guarantor, the “Parties”). W I T N E S S E T H: WHEREAS, Lender is making a loan (the “Loan”) to NOVO INTEGRATED SCIENCES, INC., a Nevada corporation (“

Novo Integrated Sciences’ IoNovo for Kids Granted Registration Number and Regulatory Approval by Turkey’s Ministry of Health Partners with NOYEM Global Foreign Trade and Consultancy Inc. for Distribution in Turkey

Exhibit 99.1 Novo Integrated Sciences’ IoNovo for Kids Granted Registration Number and Regulatory Approval by Turkey’s Ministry of Health Partners with NOYEM Global Foreign Trade and Consultancy Inc. for Distribution in Turkey BELLEVUE, Wash., September 13, 2023 – Novo Integrated Sciences, Inc. (NASDAQ: NVOS) (the “Company” or “Novo”), today announced that its IoNovo for Kids pure iodine oral spra

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest reported): September 13, 2023 Novo Integrated Scienc

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest reported): September 13, 2023 Novo Integrated Sciences, Inc.

Novo Integrated Sciences Provides Update on Potential Share Repurchase Program

Exhibit 99.1 Novo Integrated Sciences Provides Update on Potential Share Repurchase Program BELLEVUE, Wash., September 8, 2023 - Novo Integrated Sciences, Inc. (NASDAQ: NVOS) (the “Company” or “Novo”), today provides an update with respect to the Company’s Board of Directors (the “Board”) conducting a strategic review of the Company to include implementing a future share repurchase program. The Bo

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest reported): September 8, 2023 Novo Integrated Science

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest reported): September 8, 2023 Novo Integrated Sciences, Inc.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest reported): August 31, 2023 Novo Integrated Sciences,

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest reported): August 31, 2023 Novo Integrated Sciences, Inc.

Novo Integrated Sciences Receives Underwriter Clearance Notice for $70,000,000 Coupon Compliance Review Affirmed for Completion of Debt Funding Transaction

Exhibit 99.1 Novo Integrated Sciences Receives Underwriter Clearance Notice for $70,000,000 Coupon Compliance Review Affirmed for Completion of Debt Funding Transaction BELLEVUE, Wash., August 31, 2023 - Novo Integrated Sciences, Inc. (NASDAQ: NVOS) (the “Company” or “Novo”), today announced the Company received an Underwriting Clearance Notice from RC Consulting Group LLC informing Novo that the

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest reported): December 29, 2022 Novo Integrated Science

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest reported): December 29, 2022 Novo Integrated Sciences, Inc.

Acenzia Selected to join Team Canada Trade Mission to India Team Canada Delegation to be led by Honorable Mary Ng, Canada’s Minister of International Trade, Export Promotion, Small Business and Economic Development

Exhibit 99.1 Acenzia Selected to join Team Canada Trade Mission to India Team Canada Delegation to be led by Honorable Mary Ng, Canada’s Minister of International Trade, Export Promotion, Small Business and Economic Development BELLEVUE, Wash., August 24, 2023 – Novo Integrated Sciences, Inc. (NASDAQ: NVOS) (the “Company” or “Novo”), today announced that Acenzia, a nutraceutical manufacturer and a

Regulation FD Disclosure, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest reported): August 24, 2023 Novo Integrated Sciences, Inc.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest reported): August 22, 2023 Novo Integrated Sciences,

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest reported): August 22, 2023 Novo Integrated Sciences, Inc.

Novo Integrated Sciences’ IoNovo Iodine Granted Registration Number and Regulatory Approval by Turkey’s Ministry of Health

Exhibit 99.1 Novo Integrated Sciences’ IoNovo Iodine Granted Registration Number and Regulatory Approval by Turkey’s Ministry of Health BELLEVUE, Wash., August 22, 2023 – Novo Integrated Sciences, Inc. (NASDAQ: NVOS) (the “Company” or “Novo”), today announced that its IoNovo Iodine product has been granted a registration number and received regulatory approval by Turkey’s Ministry of Health as a d

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. )

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Defin

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. )

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defin

Novo Integrated Sciences Provides Update on Certain Current Actions and Events

Exhibit 99.1 Novo Integrated Sciences Provides Update on Certain Current Actions and Events BELLEVUE, Wash., August 15, 2023 - Novo Integrated Sciences, Inc. (NASDAQ: NVOS) (the “Company” or “Novo”), today provides an update with respect to certain actions and events, as follows: ● Parties continue to work toward closing SWAG Agreement: As previously disclosed, Novo entered into a share purchase a

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest reported): August 15, 2023 Novo Integrated Sciences,

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest reported): August 15, 2023 Novo Integrated Sciences, Inc.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest reported): August 15, 2023 Novo Integrated Sciences,

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest reported): August 15, 2023 Novo Integrated Sciences, Inc.

Novo Integrated Sciences and Farm 7 Group Announce Joint Venture for Kenya Cooperative Agricultural Project Food-based commodity farming on up to 9 million hectares in Kenya

Exhibit 99.1 Novo Integrated Sciences and Farm 7 Group Announce Joint Venture for Kenya Cooperative Agricultural Project Food-based commodity farming on up to 9 million hectares in Kenya BELLEVUE, Wash., August 15, 2023 - Novo Integrated Sciences, Inc. (NASDAQ: NVOS) (the “Company” or “Novo”) today announced the Company and Farm 7 Group Inc., a Canada corporation (“F7”), have entered into a joint

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. )

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defin

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended May 31, 2023 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from , 20, to , 20. Commission File Number 001-40089 Novo Integrated

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest reported): July 17, 2023 Novo Integrated Sciences, I

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest reported): July 17, 2023 Novo Integrated Sciences, Inc.

Novo Integrated Sciences Reports Fiscal Year 2023 Third Quarter Financial Results

Exhibit 99.1 Novo Integrated Sciences Reports Fiscal Year 2023 Third Quarter Financial Results BELLEVUE, Wash., July 17, 2023 - Novo Integrated Sciences, Inc. (NASDAQ:NVOS) (the “Company” or “Novo”), pioneering a holistic approach to patient-first health and wellness through a multidisciplinary healthcare ecosystem of multiple patient and consumer touchpoints for services and product innovation, t

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest reported): July 7, 2023 Novo Integrated Sciences, In

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest reported): July 7, 2023 Novo Integrated Sciences, Inc.

Separation and General Release Agreement, dated as of June 28, 2023, by and between Novo Integrated Sciences, Inc., Jim Zsebok, and RTZ Consulting Group, Inc. (incorporated by reference to Exhibit 10.1 to the registrant’s Current Report on Form 8-K filed with the Commission on July 3, 2023).

Exhibit 10.1 Separation and General Release Agreement Dated as of June 28, 2023 This Separation and General Release Agreement (this “Agreement”), dated as of the date first set forth above (the “Effective Date”), is entered into by and between Novo Integrated Sciences, Inc., a Nevada corporation (the “Company”), Jim Zsebok (“Zsebok”) and RTZ Consulting Group, Inc., an entity owned by Zsebok (“RTZ”

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest reported): June 28, 2023 Novo Integrated Sciences, I

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest reported): June 28, 2023 Novo Integrated Sciences, Inc.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest reported): June 20, 2023 Novo Integrated Sciences, I

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest reported): June 20, 2023 Novo Integrated Sciences, Inc.

Common Stock Purchase Warrant, dated as of June 20, 2023, by and between Novo Integrated Sciences, Inc. and Mast Hill Fund, L.P. (incorporated by reference to Exhibit 4.1 to the registrant’s Current Report on Form 8-K filed with the Commission on June 26, 2023).

Exhibit 4.1 NEITHER THIS SECURITY NOR THE SECURITIES AS TO WHICH THIS SECURITY MAY BE EXERCISED HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REG

Promissory Note, dated as of June 20, 2023, by and between Novo Integrated Sciences, Inc. and Mast Hill Fund, L.P. (incorporated by reference to Exhibit 10.1 to the registrant’s Current Report on Form 8-K filed with the Commission on June 26, 2023).

Exhibit 10.1 NEITHER THE ISSUANCE AND SALE OF THE SECURITIES REPRESENTED BY THIS CERTIFICATE NOR THE SECURITIES INTO WHICH THESE SECURITIES ARE CONVERTIBLE HAVE BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR APPLICABLE STATE SECURITIES LAWS. THE SECURITIES MAY NOT BE OFFERED FOR SALE, SOLD, TRANSFERRED OR ASSIGNED (I) IN THE ABSENCE OF (A) AN EFFECTIVE REGISTRATION STATEMENT FOR

Securities Purchase Agreement, dated as of June 20, 2023, by and between Novo Integrated Sciences, Inc. and Mast Hill Fund, L.P. (incorporated by reference to Exhibit 10.2 to the registrant’s Current Report on Form 8-K filed with the Commission on June 26, 2023).

Exhibit 10.2 SECURITIES PURCHASE AGREEMENT This SECURITIES PURCHASE AGREEMENT (the “Agreement”), dated as of June 20, 2023, by and between NOVO INTEGRATED SCIENCES, INC., a Nevada corporation, with headquarters located at 11120 NE 2nd Street, Suite 100, Bellevue, WA 98004 (the “Company”), and MAST HILL FUND, L.P., a Delaware limited partnership, with its address at 48 Parker Road, Wellesley, MA 02

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest reported): June 6, 2023 Novo Integrated Sciences, In

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest reported): June 6, 2023 Novo Integrated Sciences, Inc.

Novo Integrated Sciences Receives $40,000,000 Commitment to Develop Eldercare Facilities in Canada Joint Venture Collaboration with Sheikh Khaled bin Mohammad bin Fahad Al Thanayan and his Global Healthcare Organization

EX-99.1 2 ex99-1.htm Exhibit 99.1 Novo Integrated Sciences Receives $40,000,000 Commitment to Develop Eldercare Facilities in Canada Joint Venture Collaboration with Sheikh Khaled bin Mohammad bin Fahad Al Thanayan and his Global Healthcare Organization BELLEVUE, Wash., June 6, 2023 - Novo Integrated Sciences, Inc. (NASDAQ: NVOS) (the “Company” or “Novo”) today announced the Company has received a

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest reported): May 26, 2023 Novo Integrated Sciences, In

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest reported): May 26, 2023 Novo Integrated Sciences, Inc.

Novo Integrated Sciences Reports Fiscal Year 2023 Second Quarter Financial Results

Exhibit 99.1 Novo Integrated Sciences Reports Fiscal Year 2023 Second Quarter Financial Results BELLEVUE, Wash., May 26, 2023 - Novo Integrated Sciences, Inc. (NASDAQ:NVOS) (the “Company” or “Novo”), pioneering a holistic approach to patient-first health and wellness through a multidisciplinary healthcare ecosystem of multiple patient and consumer touchpoints for services and product innovation, t

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended February 28, 2023 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from , 20, to , 20. Commission File Number 001-40089 Novo Integ

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest reported): May 26, 2023 Novo Integrated Sciences, In

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest reported): May 26, 2023 Novo Integrated Sciences, Inc.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest reported): May 23, 2023 Novo Integrated Sciences, In

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest reported): May 23, 2023 Novo Integrated Sciences, Inc.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest reported): May 24, 2023 Novo Integrated Sciences, In

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest reported): May 24, 2023 Novo Integrated Sciences, Inc.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended November 30, 2022 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from , 20, to , 20. Commission File Number 001-40089 Novo Integ

Novo Integrated Sciences Reports Fiscal Year 2023 First Quarter Financial Results

Exhibit 99.1 Novo Integrated Sciences Reports Fiscal Year 2023 First Quarter Financial Results BELLEVUE, Wash., May 24, 2023 - Novo Integrated Sciences, Inc. (NASDAQ:NVOS) (the “Company” or “Novo”), pioneering a holistic approach to patient-first health and wellness through a multidisciplinary healthcare ecosystem of multiple patient and consumer touchpoints for services and product innovation, to

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest reported): April 26, 2023 Novo Integrated Sciences,

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest reported): April 26, 2023 Novo Integrated Sciences, Inc.

Novo Integrated Sciences Signs Agreements for an Unsecured, Non- dilutive Debt Instrument with a Principal Sum of $70,000,000 The Company to Receive a Lump Sum of $57,000,000 Note has a non-compounding yield of 1.52% (zero coupon) per annum

Exhibit 99.1 Novo Integrated Sciences Signs Agreements for an Unsecured, Non- dilutive Debt Instrument with a Principal Sum of $70,000,000 The Company to Receive a Lump Sum of $57,000,000 Note has a non-compounding yield of 1.52% (zero coupon) per annum BELLEVUE, Wash., April 27, 2023 - Novo Integrated Sciences, Inc. (NASDAQ: NVOS) (the “Company” or “Novo”), today announced the issuance of an unse

Securities Purchase Agreement, dated as of April 26, 2023, by and between the registrant and RC Consulting Group LLC in favor of SCP Tourbillion Monaco (incorporated by reference to Exhibit 10.1 to the registrant’s Current Report on Form 8-K filed with the Commission on April 27, 2023).

Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This SECURITIES PURCHASE AGREEMENT (the “Agreement”), dated as of April 26, 2023, by and between NOVO INTEGRATED SCIENCES, INC., a Nevada corporation, with headquarters located at 11120 NE 2nd Street, Suite 100, Bellevue, WA 98004 (the “Company”), and RC Consulting Group LLC, a North Carolina Limited Liability Corporation, with its address at 4311 School

Promissory Note, dated as of April 26, 2023, issued by the registrant to RC Consulting Group LLC in favor of SCP Tourbillion Monaco. (incorporated by reference to Exhibit 10.2 to the registrant’s Current Report on Form 8-K filed with the Commission on April 27, 2023)

Exhibit 10.2 NEITHER THE ISSUANCE AND SALE OF THE SECURITIES REPRESENTED BY THIS CERTIFICATE NOR THE SECURITIES INTO WHICH THESE SECURITIES ARE CONVERTIBLE HAVE BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR APPLICABLE STATE SECURITIES LAWS. THE SECURITIES MAY NOT BE OFFERED FOR SALE, SOLD, TRANSFERRED OR ASSIGNED (I) IN THE ABSENCE OF (A) AN EFFECTIVE REGISTRATION STATEMENT FOR

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest reported): April 20, 2023 Novo Integrated Sciences,

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest reported): April 20, 2023 Novo Integrated Sciences, Inc.

NOVO INTEGRATED SCIENCES, INC. (Name of Registrant as Specified in Charter)

UNITED STATES OMB APPROVAL SECURITIES AND EXCHANGE COMMISSION OMB Number: 3235-0058 Washington, D.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest reported): April 3, 2023 Novo Integrated Sciences, I

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest reported): April 3, 2023 Novo Integrated Sciences, Inc.

Letter Agreement, dated December 13, 2022, by and among the Company, Terragenx Inc. and Jefferson Street Capital LLC (incorporated by reference to Exhibit 10.49 to the Company’s Annual Report on Form 10-K filed with the Commission on April 3, 2023).

Exhibit 10.49 NOVO INTEGRATED SCIENCES INC. December 13, 2022 Jefferson Street Capital LLC 720 Monroe Street, C401B Hoboken, New Jersey 07030 Attn: Brian Goldberg, Managing Member Re. Securities Purchase Agreement, dated as of November 17, 2021 Sir/Madam: Reference is hereby made to that certain Securities Purchase Agreement, dated as of November 17, 2021 (as may hereafter be further amended or re

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 10-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended August 31, 2022 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from , 20 , to , 20. Commission File Number 001-40089 Novo Integrated Sci

Subsidiaries of the Company.

Exhibit 21.1 LIST OF SUBSIDIARIES The following is a list of the direct and indirect subsidiaries of Novo Integrated Sciences, Inc. as of August 31, 2022. Company Jurisdiction of Incorporation or Organization Novo Healthnet Limited (1) Ontario, Canada Novomerica Health Group, Inc. (1) Nevada PRO-DIP, LLC (1) New York Acenzia, Inc. (2) Ontario, Canada Terragenx Inc. (3) Canada Clinical Consultants

Novo Integrated Sciences Reports Fiscal Full Year 2022 Financial Results

Exhibit 99.1 Novo Integrated Sciences Reports Fiscal Full Year 2022 Financial Results BELLEVUE, Wash., April 3, 2023 - Novo Integrated Sciences, Inc. (NASDAQ:NVOS) (the “Company” or “Novo”), pioneering a holistic approach to patient-first health and wellness through a multidisciplinary healthcare ecosystem of multiple patient and consumer touchpoints providing services and product innovation, toda

Promissory Note, dated as of March 21, 2023, by and between Novo Integrated Sciences, Inc. and FirstFire Global Opportunities Fund, LLC (incorporated by reference to Exhibit 10.1 to the registrant’s Current Report on Form 8-K filed with the Commission on March 27, 2023).

Exhibit 10.1 NEITHER THE ISSUANCE AND SALE OF THE SECURITIES REPRESENTED BY THIS CERTIFICATE NOR THE SECURITIES INTO WHICH THESE SECURITIES ARE CONVERTIBLE HAVE BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR APPLICABLE STATE SECURITIES LAWS. THE SECURITIES MAY NOT BE OFFERED FOR SALE, SOLD, TRANSFERRED OR ASSIGNED (I) IN THE ABSENCE OF (A) AN EFFECTIVE REGISTRATION STATEMENT FOR

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest reported): March 21, 2023 Novo Integrated Sciences,

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest reported): March 21, 2023 Novo Integrated Sciences, Inc.

Securities Purchase Agreement, dated as of March 21, 2023, by and between Novo Integrated Sciences, Inc. and FirstFire Global Opportunities Fund, LLC (incorporated by reference to Exhibit 10.2 to the registrant’s Current Report on Form 8-K filed with the Commission on March 27, 2023).

Exhibit 10.2 SECURITIES PURCHASE AGREEMENT This SECURITIES PURCHASE AGREEMENT (the “Agreement”), dated as of March 21, 2023, by and between NOVO INTEGRATED SCIENCES, INC., a Nevada corporation, with headquarters located at 11120 NE 2nd Street, Suite 100, Bellevue, WA 98004 (the “Company”), and FIRSTFIRE GLOBAL OPPORTUNITIES FUND, LLC, a Delaware limited liability company, with its address at 1040

Common Stock Purchase Warrant, dated as of March 21, 2023, by and between Novo Integrated Sciences, Inc. and FirstFire Global Opportunities Fund, LLC (incorporated by reference to Exhibit 4.1 to the Company’s Current Report on Form 8-K filed with the Commission on March 27, 2023).

Exhibit 4.1 NEITHER THIS SECURITY NOR THE SECURITIES AS TO WHICH THIS SECURITY MAY BE EXERCISED HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REG

Novo Integrated Sciences Provides Update on Certain Current Actions and Events

Exhibit 99.1 Novo Integrated Sciences Provides Update on Certain Current Actions and Events BELLEVUE, Wash., March 24, 2023 - Novo Integrated Sciences, Inc. (NASDAQ: NVOS) (the “Company” or “Novo”), today provides an update with respect to certain actions and events, as follows: ● As previously reported, on December 23, 2022, Novo entered into a Share Purchase Agreement (the “SWAG Agreement”) with

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest reported): March 24, 2023 Novo Integrated Sciences,

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest reported): March 24, 2023 Novo Integrated Sciences, Inc.

Securities Purchase Agreement, dated as of February 23, 2023, by and between Novo Integrated Sciences, Inc. and Mast Hill Fund, L.P. (incorporated by reference to Exhibit 10.2 to the registrant’s Current Report on Form 8-K filed with the Commission on March 1, 2023).

EX-10.2 4 ex10-2.htm Exhibit 10.2 SECURITIES PURCHASE AGREEMENT This SECURITIES PURCHASE AGREEMENT (the “Agreement”), dated as of February 23, 2023, by and between NOVO INTEGRATED SCIENCES, INC., a Nevada corporation, with headquarters located at 11120 NE 2nd Street, Suite 100, Bellevue, WA 98004 (the “Company”), and MAST HILL FUND, L.P., a Delaware limited partnership, with its address at 48 Park

Common Stock Purchase Warrant, dated as of February 23, 2023, by and between Novo Integrated Sciences, Inc. and Mast Hill Fund, L.P. (incorporated by reference to Exhibit 4.1 to the Company’s Current Report on Form 8-K filed with the Commission on March 1, 2023).

Exhibit 4.1 NEITHER THIS SECURITY NOR THE SECURITIES AS TO WHICH THIS SECURITY MAY BE EXERCISED HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REG

Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest reported): February 23, 2023 Novo Integrated Sciences, Inc.

Promissory Note, dated as of February 23, 2023, by and between Novo Integrated Sciences, Inc. and Mast Hill Fund, L.P. (incorporated by reference to Exhibit 10.1 to the registrant’s Current Report on Form 8-K filed with the Commission on March 1, 2023).

Exhibit 10.1 NEITHER THE ISSUANCE AND SALE OF THE SECURITIES REPRESENTED BY THIS CERTIFICATE NOR THE SECURITIES INTO WHICH THESE SECURITIES ARE CONVERTIBLE HAVE BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR APPLICABLE STATE SECURITIES LAWS. THE SECURITIES MAY NOT BE OFFERED FOR SALE, SOLD, TRANSFERRED OR ASSIGNED (I) IN THE ABSENCE OF (A) AN EFFECTIVE REGISTRATION STATEMENT FOR

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest reported): February 9, 2023 Novo Integrated Sciences

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest reported): February 9, 2023 Novo Integrated Sciences, Inc.

NVOS / Novo Integrated Sciences Inc / Hudson Bay Capital Management LP - NVOS 13GA Passive Investment

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* Novo Integrated Sciences, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 67011T201 (CUSIP Number) December 31, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule

Novo Integrated Sciences Announces Receipt of Notice from Nasdaq

EX-99.1 2 ex99-1.htm Exhibit 99.1 Novo Integrated Sciences Announces Receipt of Notice from Nasdaq BELLEVUE, Wash., January 30, 2023 - Novo Integrated Sciences, Inc. (NASDAQ: NVOS) (the “Company” or “Novo”), today reported that it received a notice on January 25, 2023 from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) advising the Company that it was not in compli

Regulation FD Disclosure, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Unregistered Sales of Equity Securities, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest reported): January 25, 2023 Novo Integrated Sciences, Inc.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest reported): January 17, 2023 Novo Integrated Sciences

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest reported): January 17, 2023 Novo Integrated Sciences, Inc.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest reported): January 17, 2023 Novo Integrated Sciences

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest reported): January 17, 2023 Novo Integrated Sciences, Inc.

Novo Integrated Sciences Provides Update on Certain Current Actions and Events

Exhibit 99.1 Novo Integrated Sciences Provides Update on Certain Current Actions and Events BELLEVUE, Wash., January 17, 2023 - Novo Integrated Sciences, Inc. (NASDAQ: NVOS) (the “Company” or “Novo”), today provides an update with respect to certain actions and events, as follows: ● As previously reported, on December 23, 2022, Novo entered into a Share Purchase Agreement (the “SWAG Agreement”) wi

NOVO INTEGRATED SCIENCES, INC. (Name of Registrant as Specified in Charter)

UNITED STATES OMB APPROVAL SECURITIES AND EXCHANGE COMMISSION OMB Number: 3235-0058 Washington, D.

Entry into a Material Definitive Agreement, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest reported): December 30, 2022 Novo Integrated Sciences, Inc.

Amendment No. 1 to Share Purchase Agreement, dated as of December 30, 2022, by and among Novo Integrated Sciences, Inc., SwagCheck Inc. and the shareholders of SwagCheck Inc.

EX-10.1 2 ex10-1.htm Exhibit 10.1 Amendment No. 1 to Share Purchase Agreement Dated as of December 30, 2022 This Amendment No. 1 to Share Purchase Agreement, (this “Amendment”) is entered into as of the date first set forth above (the “Amendment Date”), by and among (i) Novo Integrated Sciences, Inc., a Nevada corporation (the Company”); (ii) SwagCheck Inc.., a Delaware corporation (“SWAG”); and (

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14C Information Statement Pursuant to Section 14(c) of the Securities Exchange Act of 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14C Information Statement Pursuant to Section 14(c) of the Securities Exchange Act of 1934 Check the appropriate box: ? Preliminary Information Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14c-5(d)(2)) ? Definitive Information Statement Novo Integrated Sciences, Inc. (Name of Registra

Entry into a Material Definitive Agreement, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest reported): December 23, 2022 Novo Integrated Sciences, Inc.

Share Purchase Agreement, dated as of December 23, 2022, by and among Novo Integrated Sciences, Inc., SwagCheck Inc. and the shareholders of SwagCheck Inc. (incorporated by reference to Exhibit 10.1 to the Company’s Current Report on Form 8-K filed with the Commission on December 30, 2022).

Exhibit 10.1 SHARE PURCHASE AGREEMENT by and among Novo Integrated Sciences, Inc., SwagCheck Inc. and the shareholders of SwagCheck Inc. - ii - TABLE OF CONTENTS Article I. DEFINITIONS 1 Section 1.01 Definitions. 1 Section 1.02 Interpretive Provisions. 6 Article II. SHARE PURCHASE 8 Section 2.01 Purchased Shares. 8 Section 2.02 Purchase Price. 8 Section 2.03 Satisfaction of Purchase Price. 8 Secti

Regulation FD Disclosure, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest reported): December 15, 2022 Novo Integrated Sciences, Inc.

Novo Integrated Sciences Announces Receipt of Notice from Nasdaq

Exhibit 99.1 Novo Integrated Sciences Announces Receipt of Notice from Nasdaq BELLEVUE, Wash., December 21, 2022 - Novo Integrated Sciences, Inc. (NASDAQ: NVOS) (the ?Company? or ?Novo?), today reported that it received a notice (the ?Notice) on December 15, 2022 from the Listing Qualifications Department of The Nasdaq Stock Market LLC (?Nasdaq?) advising the Company that it was not in compliance

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14C Information Statement Pursuant to Section 14(c) of the Securities Exchange Act of 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14C Information Statement Pursuant to Section 14(c) of the Securities Exchange Act of 1934 Check the appropriate box: ☒ Preliminary Information Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14c-5(d)(2)) ☐ Definitive Information Statement Novo Integrated Sciences, Inc. (Name of Registra

Novo Integrated Sciences’ Subsidiary, Clinical Consultants International, Signs Consulting Agreement with Pharmaceutical Research & Development Company, Sarfez Pharmaceuticals, Inc.

Exhibit 99.1 Novo Integrated Sciences? Subsidiary, Clinical Consultants International, Signs Consulting Agreement with Pharmaceutical Research & Development Company, Sarfez Pharmaceuticals, Inc. BELLEVUE, Wash., November 30, 2022 - Novo Integrated Sciences, Inc. (NASDAQ: NVOS) (the ?Company? or ?Novo?), and Clinical Consultants International LLC (?CCI?), a Novo wholly-owned subsidiary, today annou

Regulation FD Disclosure, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest reported): November 30, 2022 Novo Integrated Sciences, Inc.

NOVO INTEGRATED SCIENCES, INC. (Name of Registrant as Specified in Charter)

NT 10-K 1 formnt10-k.htm UNITED STATES OMB APPROVAL SECURITIES AND EXCHANGE COMMISSION OMB Number: 3235-0058 Washington, D.C. 20549 Expires: April 30, 2025 Estimated average burden hours per response ... 2.50 FORM 12b-25 001-40089 NOTIFICATION OF LATE FILING SEC FILE NUMBER (Check one): ☒ Form 10-K ☐ Form 20-F ☐ Form 11-K ☐ Form 10-Q ☐ Form 10-D ☐ Form N-SAR ☐ Form N-CSR For Period Ended: August 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest reported): November 21, 2022 Novo Integrated Science

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest reported): November 21, 2022 Novo Integrated Sciences, Inc.

Exchange Offer and Amendment, dated as of November 14, 2022, by and between the registrant and Hudson Bay Master Fund Ltd. (incorporated by reference to Exhibit 10.2 to the Company’s Current Report on Form 8-K filed with the Commission on November 15, 2022).

Exhibit 10.2 November 14, 2022 Holder of December 14, 2021 Warrant to Purchase Common Stock and Holders of Senior Secured Convertible Notes Re: Exchange Offer of Warrants to Purchase Common Stock and Amendment of Certain Senior Secured Convertible Notes Dear Holder: Novo Integrated Sciences, Inc., a Nevada corporation (the “Company”), is pleased to offer to you the opportunity to exchange certain

Exchange Offer and Amendment, dated as of November 14, 2022, by and between the registrant and CVI Investments, Inc. (incorporated by reference to Exhibit 10.1 to the Company’s Current Report on form 8-K filed with the Commission on November 15, 2022).

Exhibit 10.1 November 14, 2022 Holder of December 14, 2021 Warrant to Purchase Common Stock and Holders of Senior Secured Convertible Notes Re: Exchange Offer of Warrants to Purchase Common Stock and Amendment of Certain Senior Secured Convertible Notes Dear Holder: Novo Integrated Sciences, Inc., a Nevada corporation (the “Company”), is pleased to offer to you the opportunity to exchange certain

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest reported): November 14, 2022 Novo Integrated Science

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest reported): November 14, 2022 Novo Integrated Sciences, Inc.

Form of Five Year Common Stock Purchase Warrant (incorporated by reference to Exhibit 4.2 to the Company’s Current Report on Form 8-K filed with the Commission on October 18, 2022).

Exhibit 4.2 UNLESS THIS CERTIFICATE IS PRESENTED BY AN AUTHORIZED REPRESENTATIVE OF THE DEPOSITORY TRUST COMPANY, A NEW YORK CORPORATION (?DTC?), TO THE COMPANY OR ITS AGENT FOR REGISTRATION OF TRANSFER, EXCHANGE, OR PAYMENT, AND ANY CERTIFICATE ISSUED IS REGISTERED IN THE NAME OF CEDE & CO. OR IN SUCH OTHER NAME AS IS REQUESTED BY AN AUTHORIZED REPRESENTATIVE OF DTC (AND ANY PAYMENT IS MADE TO CE

Form of Three Year Common Stock Purchase Warrant (incorporated by reference to Exhibit 4.1 to the Company’s Current Report on Form 8-K filed with the Commission on October 18, 2022).

Exhibit 4.1 UNLESS THIS CERTIFICATE IS PRESENTED BY AN AUTHORIZED REPRESENTATIVE OF THE DEPOSITORY TRUST COMPANY, A NEW YORK CORPORATION (?DTC?), TO THE COMPANY OR ITS AGENT FOR REGISTRATION OF TRANSFER, EXCHANGE, OR PAYMENT, AND ANY CERTIFICATE ISSUED IS REGISTERED IN THE NAME OF CEDE & CO. OR IN SUCH OTHER NAME AS IS REQUESTED BY AN AUTHORIZED REPRESENTATIVE OF DTC (AND ANY PAYMENT IS MADE TO CE

Warrant Agency Agreement, dated October 18, 2022, by and between the registrant and Pacific Stock Transfer Company (incorporated by reference to Exhibit 4.3 to the Company’s Current Report on Form 8-K filed with the Commission on October 18, 2022).

Exhibit 4.3 WARRANT AGENCY AGREEMENT WARRANT AGENCY AGREEMENT, dated as of October 18, 2022 (?Agreement?), between Novo Integrated Sciences, Inc., a Nevada corporation (the ?Company?), and Pacific Stock Transfer Company (the ?Warrant Agent?). W I T N E S S E T H WHEREAS, pursuant to an offering by the Company of Warrants (as defined below), the Company wishes to issue Warrants in book entry form e

Entry into a Material Definitive Agreement, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest reported): October 13, 2022 Novo Integrated Sciences, Inc.

Placement Agency Agreement, dated October 13, 2022, by and between the registrant and Maxim Group LLC, as exclusive placement agent thereunder (incorporated by reference to Exhibit 1.1 to the Company’s Current Report on Form 8-K filed with the Commission on October 18, 2022).

EX-1.1 2 ex1-1.htm Exhibit 1.1 PLACEMENT AGENCY AGREEMENT October 13, 2022 VIA ELECTRONIC DELIVERY Mr. Robert Mattacchione Chairman & Chief Executive Officer Novo Integrated Sciences, Inc. 11120 NE 2nd Street, Suite 100 Bellevue, WA 98004 Dear Mr. Mattacchione: This letter (the “Agreement”) constitutes the agreement between Maxim Group LLC (“Maxim” or the “Placement Agent”) and Novo Integrated Sci

Novo Integrated Sciences, Inc. 4,000,000 Units, each consisting of One Share of Common Stock or One Pre-Funded Warrant to Purchase One Share of Common Stock One Three-Year Warrant to Purchase One Share of Common Stock One Five-Year Warrant to Purchas

Filed Pursuant to Rule 424(b)(4) Registration No. 333-267401 Novo Integrated Sciences, Inc. 4,000,000 Units, each consisting of One Share of Common Stock or One Pre-Funded Warrant to Purchase One Share of Common Stock One Three-Year Warrant to Purchase One Share of Common Stock One Five-Year Warrant to Purchase One Share of Common Stock We are offering 4,000,000 units (?Units?), each Unit consisti

Waiver and Amendment, dated as of October 13, 2022, by and between the registrant and CVI Investments, Inc. (incorporated by reference to Exhibit 10.1 to the Company’s Current Report on Form 8-K filed with the Commission on October 14, 2022).

Exhibit 10.1 Waiver and Amendment Dated as of October 13, 2022 [CVI Investments, Inc.] This Waiver and Amendment (this ?Waiver?), dated as of the date first set forth above (the ?Waiver Date?), is entered into by and between Novo Integrated Sciences, Inc., a Nevada corporation (the ?Company?) and CVI Investments, Inc. (the ?Holder?). The Company and Holder may be referred to herein individually as

Novo Integrated Sciences, Inc. Announces Pricing of $2.0 Million Public Offering

Exhibit 99.1 Novo Integrated Sciences, Inc. Announces Pricing of $2.0 Million Public Offering BELLEVUE, Wash., October 13, 2022?(BUSINESS WIRE)?Novo Integrated Sciences, Inc. (NASDAQ: NVOS) (the ?Company? or ?Novo?), today announced the pricing of its public offering of an aggregate of 4,000,000 units at a public offering price of $0.50 per unit. Each unit consists of (i) one share of common stock

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest reported): October 13, 2022 Novo Integrated Sciences

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest reported): October 13, 2022 Novo Integrated Sciences, Inc.

Waiver and Amendment, dated as of October 13, 2022, by and between the registrant and Hudson Bay Master Fund Ltd. (incorporated by reference to Exhibit 10.2 to the Company’s Current Report on Form 8-K filed with the Commission on October 14, 2022)

Exhibit 10.2 Waiver and Amendment Dated as of October 13, 2022 [Hudson Bay Master Fund Ltd.] This Waiver and Amendment (this ?Waiver?), dated as of the date first set forth above (the ?Waiver Date?), is entered into by and between Novo Integrated Sciences, Inc., a Nevada corporation (the ?Company?) and Hudson Bay Master Fund Ltd. (the ?Holder?). The Company and Holder may be referred to herein ind

Novo Integrated Sciences, Inc. 11120 NE 2nd Street, Suite 100 Bellevue, WA 98004

Novo Integrated Sciences, Inc. 11120 NE 2nd Street, Suite 100 Bellevue, WA 98004 October 7, 2022 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, N.E. Washington, D.C. 20549 Re: Novo Integrated Sciences, Inc. Registration Statement on Form S-1 CIK No. 0001138978 File No. 333-267401 Ladies and Gentlemen: In accordance w

Filing Fee Table

Exhibit 107 CALCULATION OF FILING FEE TABLES Form S-1 (Form Type) Novo Integrated Sciences, Inc.

Form of Warrant

Exhibits 4.7 COMMON STOCK PURCHASE WARRANT NOVO INTEGRATED SCIENCES, INC. Warrant Shares: [] Issue Date: [], 2022 (?Issuance Date?) THIS COMMON STOCK PURCHASE WARRANT (the ?Warrant?) certifies that, for value received, or its assigns [] (the ?Holder?) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date he

Form of Securities Purchase Agreement

Exhibit 10.56 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this ?Agreement?) is dated as of , 2022, between Novo Integrated Sciences, Inc., a Nevada corporation (the ?Company?), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a ?Purchaser? and collectively the ?Purchasers?). WHEREAS, subject to the terms and conditions s

Form of Warrant Agency Agreement between the Company and Pacific Stock Transfer Company.

Exhibit 4.6 WARRANT AGENCY AGREEMENT WARRANT AGENCY AGREEMENT, dated as of [], 2022 (?Agreement?), between Novo Integrated Sciences, Inc., a Nevada corporation (the ?Company?), and Pacific Stock Transfer Company (the ?Warrant Agent?). W I T N E S S E T H WHEREAS, pursuant to an offering by the Company of Warrants (as defined below), the Company wishes to issue Warrants in book entry form entitling

October 7, 2022

October 7, 2022 Securities and Exchange Commission 100 F. Street, NE Washington, D.C. 20549 Re: Novo Integrated Sciences, Inc. Registration Statement on Form S-1 File No. 333-267401 VIA EDGAR Ladies and Gentlemen: Pursuant to Rule 461 of the General Rules and Regulations of the U.S. Securities and Exchange Commission under the Securities Act of 1933, as amended, Maxim Group LLC, as placement agent

Form of Pre-Funded Warrant (incorporated by reference to the Company’s Pre-Effective Amendment No. 1 to Registration Statement on Form S-1 filed on October 4, 2022).

Exhibit 4.8 PRE-FUNDED COMMON STOCK PURCHASE WARRANT NOVO INTEGRATED SCIENCES, INC. Warrant Shares: [] Issue Date: [], 2022 THIS PRE-FUNDED COMMON STOCK PURCHASE WARRANT (the ?Warrant?) certifies that, for value received [], or its assigns (the ?Holder?) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date

As filed with the U.S. Securities and Exchange Commission on October 7, 2022

As filed with the U.S. Securities and Exchange Commission on October 7, 2022 Registration No. 333-267401 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Pre-Effective Amendment No. 2 to Form S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 NOVO INTEGRATED SCIENCES, INC. (Exact name of registrant as specified in its charter) Nevada 8000 59-3691650 (State or other

Form of Placement Agency Agreement by and between the Company and Maxim Group, LLC

Exhibit 1.1 PLACEMENT AGENCY AGREEMENT [], 2022 VIA ELECTRONIC DELIVERY Mr. Robert Mattacchione Chairman & Chief Executive Officer Novo Integrated Sciences, Inc. 11120 NE 2nd Street, Suite 100 Bellevue, WA 98004 Dear Mr. Mattacchione: This letter (the ?Agreement?) constitutes the agreement between Maxim Group LLC (?Maxim? or the ?Placement Agent?) and Novo Integrated Sciences, Inc., a Nevada corpo

Form of Pre-Funded Warrant

Exhibit 4.8 PRE-FUNDED COMMON STOCK PURCHASE WARRANT NOVO INTEGRATED SCIENCES, INC. Warrant Shares: [] Issue Date: [], 2022 THIS PRE-FUNDED COMMON STOCK PURCHASE WARRANT (the ?Warrant?) certifies that, for value received [], or its assigns (the ?Holder?) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date

Form of Securities Purchase Agreement

Exhibit 10.56 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this ?Agreement?) is dated as of , 2022, between Novo Integrated Sciences, Inc., a Nevada corporation (the ?Company?), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a ?Purchaser? and collectively the ?Purchasers?). WHEREAS, subject to the terms and conditions s

Form of Warrant Agency Agreement between the Company and Pacific Stock Transfer Company.

Exhibit 4.6 WARRANT AGENCY AGREEMENT WARRANT AGENCY AGREEMENT, dated as of [], 2022 (?Agreement?), between Novo Integrated Sciences, Inc., a Nevada corporation (the ?Company?), and Pacific Stock Transfer Company (the ?Warrant Agent?). W I T N E S S E T H WHEREAS, pursuant to an offering by the Company of Warrants (as defined below), the Company wishes to issue Warrants in book entry form entitling

As filed with the U.S. Securities and Exchange Commission on October 4, 2022

As filed with the U.S. Securities and Exchange Commission on October 4, 2022 Registration No. 333-267401 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Pre-Effective Amendment No. 1 to Form S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 NOVO INTEGRATED SCIENCES, INC. (Exact name of registrant as specified in its charter) Nevada 8000 59-3691650 (State or other

Form of Placement Agency Agreement by and between the Company and Maxim Group, LLC

Exhibit 1.1 PLACEMENT AGENCY AGREEMENT [], 2022 VIA ELECTRONIC DELIVERY Mr. Robert Mattacchione Chairman & Chief Executive Officer Novo Integrated Sciences, Inc. 11120 NE 2nd Street, Suite 100 Bellevue, WA 98004 Dear Mr. Mattacchione: This letter (the ?Agreement?) constitutes the agreement between Maxim Group LLC (?Maxim? or the ?Placement Agent?) and Novo Integrated Sciences, Inc., a Nevada corpo

Form of Common Stock Purchase Warrant

Exhibits 4.7 COMMON STOCK PURCHASE WARRANT NOVO INTEGRATED SCIENCES, INC. Warrant Shares: [] Issue Date: [], 2022 THIS COMMON STOCK PURCHASE WARRANT (the ?Warrant?) certifies that, for value received, or its assigns [] (the ?Holder?) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date hereof (the ?Initial

Filing Fee Table

Exhibit 107 CALCULATION OF FILING FEE TABLES Form S-1 (Form Type) Novo Integrated Sciences, Inc.

Filing Fee Table

Exhibit 107 CALCULATION OF FILING FEE TABLES Form S-1 (Form Type) Novo Integrated Sciences, Inc.

Power of Attorney (incorporated by reference to the signature page of the Company’s Registration Statement on Form S-1 filed on September 13, 2022).

As filed with the U.S. Securities and Exchange Commission on September 13, 2022 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 NOVO INTEGRATED SCIENCES, INC. (Exact name of registrant as specified in its charter) Nevada 8000 59-3691650 (State or other jurisdiction of incorporation or org

List of Subsidiaries (incorporated by reference to the Company’s Registration Statement on Form S-1 filed on September 13, 2022).

Exhibit 21.1 LIST OF SUBSIDIARIES The following is a list of the direct and indirect subsidiaries of Novo Integrated Sciences, Inc. as of September 12, 2022. Company Jurisdiction of Incorporation or Organization Novo Healthnet Limited (1) Ontario, Canada Novomerica Health Group, Inc. (1) Nevada PRO-DIP, LLC (1) New York Acenzia, Inc. (2) Ontario, Canada Terragenx Inc. (3) Canada Clinical Consultan

Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest reported): August 19, 2022 Novo Integrated Sciences, Inc.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest reported): August 4, 2022 Novo Integrated Sciences,

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest reported): August 4, 2022 Novo Integrated Sciences, Inc.

Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest reported): August 4, 2022 Novo Integrated Sciences, Inc.

Changes in Registrant's Certifying Accountant, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest reported): July 27, 2022 Novo Integrated Sciences, Inc.

Letter, dated July 29, 2022, from SRCO Professional Corporation addressed to the Commission.

Exhibit 16.1 SRCO Professional Corporation Chartered Professional Accountants Licensed Public Accountants Park Place Corporate Centre 15 Wertheim Court, Suite 409 Richmond Hill, ON L4B 3H7 Tel: 905 882 9500 & 416 671 7292 Fax: 905 882 9580 Email: [email protected] July 29, 2022 Securities and Exchange Commission 100 F Street, N.E. Washington, DC 20549 Re: Novo Integrated Sciences, Inc. We have read Ite

Novo Integrated Sciences Reports Record Revenue of $13.8 million in Fiscal 2022 Third Quarter Revenue Increased 382% Sequentially and 481% Year-to-Year for the Fiscal 2022 Third Quarter

Exhibit 99.1 Novo Integrated Sciences Reports Record Revenue of $13.8 million in Fiscal 2022 Third Quarter Revenue Increased 382% Sequentially and 481% Year-to-Year for the Fiscal 2022 Third Quarter BELLEVUE, Wash., July 14, 2022?(BUSINESS WIRE)?Novo Integrated Sciences, Inc. (NASDAQ: NVOS) (the ?Company? or ?Novo?), pioneering a holistic approach to patient-first health and wellness through a mul